Insomnia Raises Risk of Developing High Blood Pressure

Published Online: Thursday, August 16, 2012
Follow Pharmacy_Times:
As if tossing and turning in bed weren’t bad enough, a new study conducted by the Henry Ford Hospital in Detroit, Michigan, revealed that the incidence of hypertension is greater in insomniacs than in those who can sleep normally. The study was presented on June 12, 2012, at the Sleep 2012 Conference in Boston.

Through an Internet-based questionnaire, researchers examined 5314 subjects with insomnia and questioned them about their sleep habits, insomnia symptoms, health routines, and presence and severity of hypertension.

“The cause of hypertension in insomniacs is due to the number of times the individual wakes up during the night as well as their sleep latency—the length of time it takes to accomplish the transition from full wakefulness to sleep,” said lead author Christopher Drake, associate scientist, Henry Ford Hospital Sleep Disorders and Research Center.

According to the National Center for Sleep Disorders Research at the National Institutes of Health, approximately 70 million Americans suffer from sleep problems; among this group, nearly 60% have a chronic disorder. The link between sleep apnea and hypertension is already well established by prior studies. The study authors also found that the higher the severity of the insomnia, the more severe the hypertension was in the study subjects.

To read more articles in this watch, click:
The Rising Prevalence of Pediatric Hypertension
Hidden Hypertensive Heart Disease Ubiquitous in African Americans

Related Articles
Several studies have reported that controlling blood pressure with medication improves cardiovascular outcomes.
New research published in the British Medical Journal has answered some of the most basic questions about treating hypertension.
Despite having adequate knowledge on cardiovascular risk factors, pharmacists and other health care professionals showed significant increases in systemic arterial hypertension and excessive weight gain across a 20-year study.
Merck has announced the US launch of its insomnia medication, suvorexant, an orexin receptor antagonist indicated for the treatment of adults who have difficulty falling or staying asleep.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times